Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients

Nephrology Dialysis Transplantation, 02/10/2012

responsiveness to erythropoiesis–stimulating agents (ESA–R) predicts renal prognosis in chronic kidney disease patients followed in nephrology practice, where end–stage renal disease is the predominant outcome and ESA is commonly used at low dose.

Print Article Summary Cat 2 CME Report